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PPM. These charges averaged about $14 PPM (P = 0.069)
and $9 PPM (P = 0.231) lower than those of risperidone
and olanzapine, respectively, a savings of 2%–3% based
on a $526 PPM mean charge. Differences in non-
antipsychotic mental health care charges PPM among
bipolar patients treated with risperidone, olanzapine, or
quetiapine were largely explained by differing patient and
treatment characteristics rather than the antipsychotic
used. After dosage levels were standardized, however,
olanzapine was associated with signiﬁcantly higher drug
acquisition costs than those of risperidone and quetiap-
ine (57% and 49% respectively; P < 0.01). Although the
difference in drug charges between risperidone and que-
tiapine was not statistically signiﬁcant, quetiapine was
associated with lower PPM resource utilization. CON-
CLUSION: Quetiapine appears to be associated with
modestly lower non-antipsychotic mental health resource
use compared to risperidone and olanzapine for treatment
of bipolar disorder.
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OBJECTIVE: This study compared treatment patterns for
bipolar disorder (BP) patients (recognized and unrecog-
nized) to those of major depression disorder (MDD)
patients without a BP claim (non-BP) during the obser-
vational period. METHODS: An employer administrative
claims database (covering several managed care health
plans from 1998–2001) was used to identify 11,464
patients diagnosed with MDD and initially treated with
antidepressants (AD). Of these, unrecognized BP (UBP)
patients received their initial BP diagnosis and/or mood
stabilizer (MS) prescription after AD initiation, while rec-
ognized BP (RBP) patients had these records on/before
AD initiation. Induced BP patients were deﬁned as those
manifesting mania within six months after starting AD.
RESULTS: BP patients accounted for 6.8% of the
research sample (3.7% UBP and 3.1% RBP). Induced BP
represented 6.6% of all BP patients. RBP patients had a
slightly lower rate of induction (6.2%) than UBP patients
(6.9%). The use of combination therapies varied in the
non-BP, UBP, and RBP patients (11%, 32%, and 43%,
respectively) (all pairwise p < 0.01). The use of MS was
less frequent among UBP than RBP patients (14% and
34%, respectively) (p < 0.0001). CONCLUSIONS: A
substantial number of AD-treated MDD patients could be
classiﬁed as bipolar (either RBP or UBP), and were at risk
for induction of mania. RBP and UBP patients initiated
with more combination therapies, as compared to Non-
BP patients. MS use increased when BP was recognized.
More effort is needed to quickly diagnose and effectively
treat BP patients.
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OBJECTIVES: A Markov model was developed to deter-
mine costs and outcomes of one year of antipsychotic
treatment for patients with schizophrenia. METHODS:
The model simulated a 4-armed, randomized, parallel,
12-month observational study of 2000 inpatients and
2000 outpatients initiating treatment on ziprasidone (Z),
risperidone (R), olanzapine (O), or haloperidol (H).
Equivalent efﬁcacy between treatments was assumed;
however, relapse rates on haloperidol were adjusted to be
consistent with Csernansky et al. 2002. Weighted aver-
ages were used for published treatment-emergent adverse
event rates for akathesia (Z = 7.9, R = 15.1, O = 7.8, H
= 20.8), other extrapyridimal symptoms (Z = 11.5, R =
9.0, O = 11.6, H = 26.7), weight gain (Z = 10.0, R = 14.8,
O = 28.2, H = 11.0), and prolactin-related side effects (Z
= 2.2, R = 11.2, O = 5.2, H = 3.0) to estimate tolerabil-
ity, concomitant medication use, treatment changes, 
non-compliance, and relapse. Costs for inpatient care,
sub-acute chronic care, and outpatient visits were based
on published private and public medical claims databases.
Medication costs were $170.63/month (Z = 120mg/d),
$242.61/month (R = 4.8mg/d), $344.17 (O = 13.2mg/d),
and $6.72 (H = 15mg/d) (RedBook 2002). Outcome mea-
sures included days in acute care, total direct medical
costs, and incremental costs. RESULTS: Because of
greater tolerability, estimated days in acute care were
lowest for ziprasidone (42.4) when compared to olanza-
pine (42.8), risperidone (43.1), or haloperidol (53.6). Due
to lower estimated days in acute care and lower mainte-
nance treatment drug costs, estimated annual total health-
care costs for each drug cohort (n = 1000 patients per
cohort) were lowest for those patients initiating treatment
with ziprasidone vs. risperidone (+$787,000), olanzapine
(+$964,000), or haloperidol (+$4,210,000). Sensitivity
analyses to changes in model assumptions for adverse
event, adherence, and relapse rates, and healthcare 
costs were robust to these conclusions. CONCLUSION:
Ziprasidone has an adverse event proﬁle distinct from
those of other atypical antipsychotics and lower pharma-
ceutical acquisition costs, which potentially lead to
improved outcomes and lower total direct costs.
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OBJECTIVE: To determine whether or not subtle differ-
ences between risperidone and olanzapine, two similarly-
efﬁcacious medications, are reﬂected in health care
utilization patterns, and therefore, costs, in patients with
schizophrenia receiving usual care. METHODS: A retro-
spective cohort study was conducted from the payer per-
spective in two group model managed care organizations.
Analysis of covariance and logistic regression were used
to identify outpatient cost and hospitalization differences
respectively, while adjusting for variables that may inde-
pendently inﬂuence mental health utilization and choice
of atypical agent. Patients ages 18–64 initiating risperi-
done or olanzapine between January 1997 and December
2000 diagnosed with schizophrenia or schizoaffective 
disorder in the pre-initiation year were included if they
received no atypical antipsychotics in the previous year
and were continuously enrolled one year pre through one
year post initiation. Utilization units were transformed
into 2001 costs at one site. The total post-initiation year
outpatient mental health cost derived included all mental
health outpatient visits (including urgent care) and med-
ications, and tests related to olanzapine or risperidone
monitoring. The relationship between drug exposure and
hospitalization was explored using logistic regression. 
An intent-to-treat analysis was performed. RESULTS:
Patients receiving risperidone were less costly in the post-
initiation year than patients receiving olanzapine. The
results were signiﬁcant (p < 0.05) controlling for age,
gender, coverage type, total mental health outpatient costs
in the year prior to initiation, study site, index year,
mental health comorbidities, and mental health hospital-
ization in the pre-initiation year. Seventeen percent of
olanzapine and 21% of risperidone patients were hospi-
talized in the year post initiation, a difference that was
not statistically signiﬁcant. CONCLUSIONS: Prescribers
should consider using risperidone before using olanzap-
ine when initiating therapy in a patient with schizophre-
nia who has no contraindications to either medication.
More study is needed to determine the relation-
ship between atypical choice and mental health 
hospitalization.
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OBJECTIVE: To compare pharmacotherapy patterns 
and treatment outcomes for olanzapine- versus quetia-
pine-treated hospitalized patients with schizophrenia.
METHODS: Hospitalized olanzapine- and quetiapine-
treated patients discharged with schizophrenia (ICD9:
295.xx) between 01/1999 and 09/2001 were identiﬁed
using Premier’s PerspectiveTM database, the largest U.S.
hospital drug utilization database. Outcome measures
include use of other antipsychotics, mood stabilizers, anti-
depressants, anxiolytics, and hypnotics; length of stay
(LOS); and total treatment costs were analyzed by regres-
sions, controlling diagnoses, illness severity, patient and
institution characteristics. RESULTS: Of 9433 patients
(54.8% male, mean age 41.5 years), 6699 were olanzap-
ine-treated and 2734 quetiapine-treated. After adjusting
for confounding factors, olanzapine-treated patients used
fewer psychotropic agents (-0.36, p < 0.0001) and were
less likely to switch to or augment with other atypical
antipsychotics (odds ratio (OR) = 0.71, 95% conﬁdence
interval (CI) = 0.62 - 0.81). Olanzapine-treated patients
were less likely to be treated with typical antipsychotics
(OR = 0.77, CI = 0.70 - 0.85), mood-stabilizers (OR =
0.84, CI = 0.77 - 0.93), anxiolytics (OR = 0.67, CI = 0.60
- 0.74), or anti-Parkinsonian agents (OR = 0.87, CI =
0.79 - 0.96). There was no between-group difference in
antidepressant or hypnotic use. Total costs for olanzap-
ine-treated patients were lower (-$678, p < 0.0001) as
the result of shorter LOS (-11.4%, p < 0.0001). CON-
CLUSIONS: Compared to quetiapine, olanzapine treat-
ment for hospitalized patients with schizophrenia was
associated with more favorable pharmacotherapy pat-
terns, shorter LOS, and lower costs.
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OBJECTIVES: To examine treatment patterns and
analyze differences in health services utilization and costs
for subjects receiving risperidone, olanzapine or quetiap-
ine. METHODS: This study used administrative claims
data to identify continuously enrolled subjects prescribed
atypical antipsychotics between January 1, 2000 and
December 31, 2000. Subjects were assigned to a diag-
nostic category based on the appearance of two or more
ICD-9 codes for schizophrenia, affective disorder, 
dementia, anxiety or childhood disorders during the
study period. Duration of therapy, compliance, daily
dose, daily average consumption and concomitant med-
ication use were analyzed descriptively. Subjects were
propensity score matched on baseline characteristics for
the purpose of comparing health services utilization and
cost by site of service. RESULTS: Of 6471 study subjects,
average annual days of therapy were nearly equal
between drug groups (184–186 days). However, average
annual days of therapy varied widely by diagnostic con-
dition (181 days for anxiety, 270 days for schizophrenia).
Concomitant use of psychotropic medication was
common for all 3 drugs (81%). Subjects receiving risperi-
done had an average daily dose below the recommended
target dose for schizophrenia as did olanzapine subjects
with bipolar disorder. Daily average consumption
increased slightly for risperidone and quetiapine subjects
